Review
Nature Reviews Drug Discovery 6, 650-661 (August 2007) | doi:10.1038/nrd2368
Modelling of the blood–brain barrier in drug discovery and development
Romeo Cecchelli1, Vincent Berezowski1, Stefan Lundquist2, Maxime Culot1, Mila Renftel2, Marie-Pierre Dehouck1 & Laurence Fenart1 About the authors
Abstract
The market for neuropharmaceuticals is potentially one of the largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and the fact that many neurological disorders have been largely refractory to pharmacotherapy. The brain is a delicate organ that can efficiently protect itself from harmful compounds and precisely regulate its microenvironment. Unfortunately, the same mechanisms can also prove to be formidable hurdles in drug development. An improved understanding of the regulatory interfaces that exist between blood and brain may provide novel and more effective strategies to treat neurological disorders.
- View At a Glance
Author affiliations
- Laboratoire de physiopathologie de la barrière hémato-encéphalique E.A.2465, IMPRT IFR-114, Université d'Artois, Faculté Jean Perrin, 62307 Lens, France.
- Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden.
Correspondence to: Romeo Cecchelli1 Email: romeo.cecchelli@univ-artois.fr
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Mouse syngenic in vitro blood?brain barrier model: a new tool to examine inflammatory events in cerebral endotheliumLaboratory Investigation Research Article
SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrierNature Medicine Article (01 Jul 2003)
See all 55 matches for Research
